Imatinib resistance in chronic myelogenous leukemia: an emerging challenge.
Date
2014-09
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Resistance to imatinib is a significant clinical issue, and the underlying mechanism of this resistance is multifactorial. The efficacy of imatinib in chronic myeloid leukemia (CML) in achieving a high remission rate and improving prognosis has seriously been challenged by the development of mutants of BCR-ABL gene, which resist the action of imatinib, which is a tyrosine kinase inhibitor. We present here a case of a 35-year-old male, a known case of CML on imatinib therapy, the patient eventually landed in blast crisis and succumbed to the disease and secondary infections.
Description
Keywords
Chronic myeloid leukemia, Imatinib resistance, blast crisis
Citation
Khandelwal Aparna, Kawatra Mallika, Bhandari Virendra, Yeshwante Prashant S. Imatinib resistance in chronic myelogenous leukemia: an emerging challenge. International Journal of Basic & Clinical Pharmacology. 2014 Sep-Oct ; 3(5): 908-911.